Analyst Price Target is $2.25
▼ -8.91% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Aerovate Therapeutics in the last 3 months. The average price target is $2.25, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a -8.91% upside from the last price of $2.47.
Current Consensus is
Hold
The current consensus among 6 polled investment analysts is to hold stock in Aerovate Therapeutics. This rating has held steady since May 2024, when it changed from a Buy consensus rating.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More